Survival ‘superior’ with myectomy for obstructive hypertrophic cardiomyopathy
Advances in surgical technique for septal reduction suggest ablative therapy should no longer be routinely offered, cardiologists say
Myectomy is associated with lower all-cause mortality compared with septal ablation in patients with obstructive hypertrophic cardiomyopathy who require septal reduction, a retrospective study shows.
In one of the most comprehensive outcomes studies of septal reduction therapy to date, Mayo Clinic-led researchers reviewed records for nearly 4000 patients undergoing one or other of the procedures.
They found that, compared with alcohol septal ablation (ASA), septal myectomy was associated with fewer deaths long-term among the patients, who had a median age of 54.8 years and were followed up for a mean of 6.4 years.
The 10-year all-cause mortality rate was 26.1% for patients electing ASA compared with 8.2% for those having surgery.
